Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

We believe compliance, ethics and transparency go hand in hand. Excellence in this area is a key topic for us – and is deeply anchored in our culture.

... Compliance and transparency

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Being a responsible corporate citizen means operating our business legally, ethically, respectfully and sustainably. All business areas collaborate cross-functionally to manage environmental, social and governance (ESG) risks and make a net-positive impact in our focus areas of Patient, People and Planet.

... Responsibility

At Grünenthal, our vision of a World Free of Pain aligns seamlessly with our commitment to sustainability, especially the social aspect. We regularly evaluate our products, services, and markets to ensure alignment with our sustainability objectives.

... Our responsibility approach

Grünenthal’s focus on patients is at the core of our responsibility approach. We concentrate our efforts on the key areas of patient safety, product quality, improving patients’ quality of life through innovative medicines, access to healthcare and safe pain management through the responsible use of opioids.

... Patient

How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us.

... People

We join together with our employees, partners and customers to reduce our carbon footprint, save energy and resources, and decrease waste in our value chain.

... Planet

The Grünenthal Responsible Sourcing Programme will increase transparency and help create a positive ESG impact in our supply chain and connected local communities.

... Responsible sourcing

... Corporate Citizenship

... Thalidomide

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Pain Awareness Month 2025

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Grünenthal at a glance – experience our virtual company showcase

Who are we? What are we doing? How are we doing it? Our digital company overview quickly answers big questions about Grünenthal.
Read about our key objectives and activities, as well as our recent business development highlights and financial performance. Get insights into our leadership team, strategy and financials, R&D & Pipeline, Product portfolio, Reliable Supply, Environmental & Societal Governance, and our Company culture and purpose.

Visit company showcase

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

Growing a greener future

We have planted the first 50,000 trees of our new global reforestation project. These trees help restore forests, strengthen biodiversity and support local communities, reflecting our broader commitment to protect the planet and reduce our environmental impact across our operations.

25 November 2025

MSCI confirms ‘(p) AA’ status in ESG rating

Grünenthal is taking action every day to improve patients’ lives and minimise its environmental footprint. An external assessment from MSCI recognises our industry-leading approach to environmental, social and governance topics by awarding our company a strong ‘(p) AA’ rating for the second year in ...

05 November 2025

Professor Roman Rolke, Director of the Department of Palliative Medicine at University Hospital Aachen

World Hospice & Palliative Care Day 2025: What patients teach us about life

On 11 October 2025, the Worldwide Hospice Palliative Care Alliance marks World Hospice & Palliative Care Day under the theme ’Achieving the Promise: Universal Access to Palliative Care’.

10 October 2025

EcoVadis Gold for Grünenthal

Grünenthal has once again achieved the EcoVadis Gold Medal, with a score of 79/100 and a place in the 96th percentile globally.

02 October 2025

Biopharma autoinjector capabilities expansion

CMB biopharma growth

Grünenthal PRO is expanding its biopharma autoinjector capabilities through a strategic alliance with SHL Medical. A new pre-validated assembly line at our Origgio site will help pharmaceutical and biotech partners move faster and smarter.

04 September 2025

SBTi validation milestone

Grünenthal’s near-term science-based target has been officially validated by the SBTi. This milestone confirms that our climate targets are in line with the most ambitious decarbonization trajectory recognised by the SBTi that will keep global temperature increase to 1.5°C

07 August 2025

Nebido^® licensing agreement

We have entered into a licensing agreement with Apotex Inc. to bring Nebido^® to patients in Canada.

Searchlight Pharma, Apotex’s branded medicine division, will pursue marketing authorisation and, upon regulatory approval, market and distribute the brand in Canada, one of the largest pharmaceutical markets in the world.

Learn more about the agreement in our press release

Grünenthal Report 2024/2025

Grünenthal has a clear, bold vision: a World Free of Pain. In 2024, we took big steps forward in developing innovative medicines for patients living with pain worldwide. The latest Grünenthal Report provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.

The full Grünenthal Report is available here.

Responsibility Report 2024

As a recognised leader in environmental, social, and governance (ESG) matters, we proactively pursue best-in-class corporate sustainability practices. This report reflects the accomplishments of our teams worldwide around our focus areas of Patient People and Planet. Discover how our shared commitment is shaping long-term value.

Get more insights in our latest Responsibility Report